Employees: 158
Size Alpha Teknova (TKNO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $496M, the 2676th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.88 on 18 Nov 2026.
Performance Over six months the shares gained 113.0%, against -18.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 15.4% over the last twelve months (peer median +9.8%); the operating margin is -31.6% (peer median 10.9%).
Valuation It trades at 11.0× enterprise value to sales against a peer median of 3.7× (5th most expensive of 20).
Capital Return on invested capital runs 26.0 points below its cost of capital (9.7% WACC).
Short interest Short interest is 2.5% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $46.0M | $40.5M | $37.7M | $36.7M | $41.4M |
| Revenue growth | — | +7% | +3% | -11% | — |
| Gross profit | $15.6M | $12.3M | $6.08M | $9.15M | $16.3M |
| EBITDA | -$8.18M | -$9.63M | -$18.3M | -$24.8M | -$25.4M |
| Net income | -$16.0M | -$17.3M | -$26.7M | -$36.8M | -$47.5M |
| Free cash flow | -$6.38M | -$9.89M | -$13.5M | -$26.8M | -$55.5M |
| Capital expenditure | $814,000 | $1.15M | $1.12M | $7.93M | $28.1M |
| Total debt | $27.0M | $28.3M | $30.2M | $30.5M | $42.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TKNO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.6% | -2.1% | 7th highest of 21 |
| 6-month return | +113.0% | -18.4% | 2nd highest of 21 |
| Distance from 52-week high | -16.9% | -35.5% | 5th highest of 21 |
| Revenue growth (TTM) | +15.4% | +9.8% | 6th highest of 20 |
| Operating margin | -31.6% | 10.9% | 6th lowest of 20 |
| EV / Sales | 11.0× | 3.7× | 5th most expensive of 20 |
| ROIC minus cost of capital | -26.0 pp | -2.4 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |